Alnylam Pharmaceuticals Inc.
www.alnylam.com
Latest From Alnylam Pharmaceuticals Inc.
Finance Watch: IPOs Are In A Slump, But Already Public Companies Have Rallied
Public Company Edition: The last biopharma initial public offering in the US was on 11 November, but follow-on and other offerings are generating hundreds of millions of dollars. Among RNA drug developers, Ionis issued more than $500m in new debt, while Arrowhead raised $266.8m.
Novartis And The Medicines Company: Five Things To Worry About
The $9.7bn acquisition hinges on the small interfering RNA inclisiran, but an ongoing cardiovascular outcomes trial, manufacturing hurdles, and reimbursement challenges provide subjects for concern.
AstraZeneca And Galapagos Shine At The 15th Annual Scrip Awards
The pharma, biotech and allied industries came together in London on 4 December to celebrate another year of achievement at the 15th Annual Scrip Awards, hosted by the broadcaster Fiona Bruce.
It Has Been A Long Farewell To The Medicines Company
The company Novartis is buying for $9.7bn is largely unrecognizable from the one Clive Meanwell started in 1996, grew into a multi-product hospital specialist and began to sunset in 2015 with the loss of Angiomax.
Company Information
- Industry
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
- Synthesis Technologies, Production Processes
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Cardiovascular
- Hepatic (Liver)
- Infectious & Viral Diseases
- Neurology, Nervous System
- Alias(es)
- Alnylam Holding Co.
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Alnylam Pharmaceuticals Inc.
- Senior Management
-
John M Maraganore, PhD, CEO
Jeff S Poulton, EVP, CFO
Pushkal Garg, MD, CMO
Barry Greene, Pres.
Yvonne Greenstreet, COO
Kevin Fitzgerald, PhD, SVP, CSO - Contact Info
-
Alnylam Pharmaceuticals Inc.
Phone: (617) 551-8200
300 Third St., 3rd. Fl.
Cambridge, MA 02142
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice